Precigen/$PGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Precigen
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Ticker
$PGEN
Sector
Primary listing
Employees
143
Headquarters
Website
Precigen Metrics
BasicAdvanced
$1.2B
-
-$0.43
1.87
-
Price and volume
Market cap
$1.2B
Beta
1.87
52-week high
$5.23
52-week low
$0.65
Average daily volume
14M
Financial strength
Current ratio
2.706
Quick ratio
2.601
Long term debt to equity
-71.625
Total debt to equity
-87.398
Interest coverage (TTM)
-31,484.00%
Profitability
EBITDA (TTM)
-91.858
Gross margin (TTM)
-1,213.53%
Net profit margin (TTM)
-2,868.66%
Operating margin (TTM)
-2,176.31%
Effective tax rate (TTM)
0.06%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-67.44%
Return on equity (TTM)
-668.03%
Valuation
Price to revenue (TTM)
259.853
Price to book
-31.5
Price to tangible book (TTM)
-20.75
Price to free cash flow (TTM)
-16.162
Free cash flow yield (TTM)
-6.19%
Free cash flow per share (TTM)
-0.241
Growth
Revenue change (TTM)
-1.12%
Earnings per share change (TTM)
-20.77%
3-year revenue growth (CAGR)
-34.50%
10-year revenue growth (CAGR)
-28.88%
3-year earnings per share growth (CAGR)
-2.21%
10-year earnings per share growth (CAGR)
-0.61%
What the Analysts think about Precigen
Analyst ratings (Buy, Hold, Sell) for Precigen stock.
Bulls say / Bears say
On August 15, 2025, the U.S. FDA gave full approval to Precigen’s immunotherapy Papzimeos (PRGN-2012)—the first approved treatment for recurrent respiratory papillomatosis—a major regulatory milestone that sent shares up 81% before the market opened (Reuters)
Early- and mid-stage clinical trial data for PRGN-2012 showed 51% of treated patients required no surgeries in the twelve months following treatment, pointing to strong and durable efficacy for a population with high unmet need (Reuters)
J.P. Morgan analysts estimate Papzimeos could achieve peak U.S. sales of about $250 million, signaling considerable revenue potential for this newly approved RRP therapy (Reuters)
Precigen’s first-quarter 2025 Form 10-Q reveals significant doubt about its ability to remain a going concern without either FDA approval of PRGN-2012 or new financing, highlighting acute liquidity risk (SEC)
As of March 31, 2025, Precigen reported $83.0 million in warrant liabilities—reflecting potentially substantial dilution from around 52.7 million warrants exercisable at $0.75—creating significant downside risk for shareholders (SEC)
In the first-quarter 2025 Form 10-Q, Precigen confirmed it shut down its ActoBio subsidiary and halted several clinical programs to preserve cash, increasing dependence on the binary outcome of PRGN-2012 and narrowing its pipeline (SEC)
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Precigen Financial Performance
Revenues and expenses
Precigen Earnings Performance
Company profitability
Precigen News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Precigen stock?
Precigen (PGEN) has a market cap of $1.2B as of September 19, 2025.
What is the P/E ratio for Precigen stock?
The price to earnings (P/E) ratio for Precigen (PGEN) stock is 0 as of September 19, 2025.
Does Precigen stock pay dividends?
No, Precigen (PGEN) stock does not pay dividends to its shareholders as of September 19, 2025.
When is the next Precigen dividend payment date?
Precigen (PGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Precigen?
Precigen (PGEN) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.